Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 8/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19327561 | 0.83 | PYCR1 (0.45) | PYCR1MAOBKDM4EALDH1A1TAAR1 | |
| SCHEMBL5962473 | 0.76 | TSHR (0.54) | PYCR1MAOBALDH1A1TAAR1TSHR | |
| SCHEMBL1684422 | 0.74 | MEN1 (0.55) | PYCR1MAOBALDH1A1TSHRL3MBTL1 | |
| SCHEMBL399795 | 0.73 | HRH3 (0.64) | PYCR1MAOBKDM4EALDH1A1TAAR1 | |
| SCHEMBL15128047 | 0.73 | PYCR1 (0.67) | PYCR1MAOBKDM4EALDH1A1TAAR1 | |
| SCHEMBL10138439 | 0.72 | PYCR1 (0.36) | PYCR1MAOBTSHR | |
| SCHEMBL29083510 | 0.72 | PYCR1 (0.64) | PYCR1MAOBKDM4EALDH1A1TAAR1 | |
| SCHEMBL26522392 | 0.71 | PYCR1 (0.44) | PYCR1MAOBKDM4EALDH1A1TAAR1 | |
| SCHEMBL3161510 | 0.71 | MAOB (0.52) | MAOBALDH1A1TAAR1TSHRL3MBTL1 | |
| SCHEMBL23242190 | 0.70 | PYCR1 (0.47) | PYCR1MAOBKDM4EALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232616-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150232616-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-8980326-B2 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980326-B2 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130310912-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100136063-A1 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-06-03 | — | — | US | disclosed |
| US-7638558-B2 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7618944-B2 | Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136063-A1 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides | IAPP, APP, TTR | PYCR1 2380/4885MAOB 3036/4885KDM4E 4488/4885 |
| US-20080035243-A1 | Covalent modification of metal surfaces | ITGAL, ITGA1, ITGA5 | PYCR1 2088/4885MAOB 1982/4885KDM4E 1193/4885 |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | IAPP, APP, TTR | PYCR1 1692/4885MAOB 1843/4885KDM4E 4852/4885 |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | PYCR1 1792/4885MAOB 3383/4885KDM4E 4278/4885 |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | IAPP, APP, TTR | PYCR1 2380/4885MAOB 3036/4885KDM4E 4488/4885 |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | LIPA, LPXN, CD47 | PYCR1 3302/4885MAOB 3142/4885KDM4E 4151/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | PYCR1 1557/4885MAOB 1229/4885KDM4E 2218/4885 |
| US-20100159020-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | PYCR1 1792/4885MAOB 3383/4885KDM4E 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.